REYKJAVÍK, ICELAND, AUGUST 21, 2015 – Oculis today formally completed the formation of a new Scientific and Medical Advisory Board. The board consists of five members with vast experience from ophthalmology and the pharmaceutical industry.
Dr. Anat Loewenstein is Professor of Ophthalmology and depute dean of the medical school at the Sackler Faculty of Medicine, Tel Aviv University, Israel and Chairman of the Department of Ophthalmology, Tel Aviv Sourasky Medical Center. She has managed phase II pilot studies of Oculis’, most advanced drug candidate, DexNP, in uveitis.
Dr. Akihiro Ohira, is a Professor at the Deepartment of Ophthalmology, Shimane University School of Medicine, Japan. He has managed phase II studies of DexNP in DME.
Dr. Jost Jonas is Professor and Chairman of the Department of Ophthalmology of the Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg in Germany.
Dr. Nicholas Bodor is a Graduate Research Professor Emeritus (active) at the University of Florida College of Pharmacy, Gainesville.
Ms. Maria Soffia Gottfredsdottir, is an ophthalmologist at the National University Hospital of Iceland. She has managed phase II studies of DexNP as a post-operative anti-inflammatory agent.
Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye. Oculis has developed a drug delivery platform consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application, i.e. an eye drop.
For further information on Oculis, please visit: http://www.oculispharma.com.